BRYNJELSEN SEAN, PRES, CEO, reported an open-market or private sale at Eton Pharmaceuticals, Inc. involving 47307.000000 shares for an estimated $2846462.19. Reported holdings after the transaction were 1004909.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
Form 4 relationship flags and nearby filing context
President & CEO
The shares were sold in multiple trades at prices ranging from $62.50 to $63.41. The price above reflects the weighted average sales price.
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at…
The shares were sold in multiple trades at prices ranging from $59.59 to $60.59. The price above reflects the weighted average sales price.
The shares were sold in multiple trades at prices ranging from $60.61 to $61.61. The price above reflects the weighted average sales price.
The shares were sold in multiple trades at prices ranging from $61.63 to $62.52. The price above reflects the weighted average sales price.
0 other filings
0 recent txs